RIPK1 and COVID-19: Thus, SARS-CoV-2 may be able to hijack the RIPK1-mediated host defense response to its advantage and that inhibition of RIPK1 may provide a therapeutic option for the treatment of severe COVID-19 to help ending this public health emergency.